Humira (adalimumab) 40 mg pre-filled syringes, 2 syringes — original (AbbVie, Germany) Indications. Rheumatoid arthritis Targeted cancer therapy. Drug delivery from Europe and beyond, within 4-5 days. Storage conditions are met. Payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Indications. Rheumatoid arthritis (RA).

Humira in combination with methotrexate is indicated for:

• Treatment of moderate to severe active rheumatoid arthritis in adult patients who have not had an adequate response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate;
• Treatment of active, progressive, severe active rheumatoid arthritis in adult patients who have not previously received methotrexate therapy.

Humira can be used as monotherapy in cases of methotrexate intolerance or when continued methotrexate therapy is unacceptable.

Humira has been shown to suppress the progression of structural damage joints, which was confirmed by radiography, and an improvement in functional status when used concomitantly with methotrexate.

Psoriatic Arthritis (PsA). Humira is indicated for the treatment of active and progressive psoriatic arthritis in adult patients who have not responded adequately to prior therapy with disease-modifying antirheumatic drugs (DMARDs). Humira has been shown to slow the rate of progression of peripheral joint damage, measured by radiography, in patients with symmetrical polyarticular disease, and improve functional status. Axial spondyloarthritis Ankylosing spondylitis (AS).

Humira is indicated for the treatment of adult patients with highly active ankylosing spondylitis who have not responded adequately to conventional therapy.

Axial spondyloarthritis without radiographic evidence of AS.

Humira is indicated for the treatment of adult patients with high-grade axial spondyloarthritis activity without radiographic evidence of AS but with evidence of inflammation, based on elevated CRP levels and/or magnetic resonance imaging (MRI) tomography).

Crohn's disease (CD).

Humira is indicated for the treatment of moderate to severe Crohn's disease in adult patients who have not responded to a full course of therapy. corticosteroids and/or immunosuppressants, or in the presence of intolerance or medical contraindications to such

types of therapy.

Ulcerative colitis (UC).

Humira is indicated for the treatment of moderate to severely active ulcerative colitis in adult patients who have not responded to conventional therapy, including corticosteroids and/or 6-mercaptopurine or azathioprine, or who are intolerant to or medically contraindicated for such therapy.

Plaque psoriasis (PP).

Humira is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who require systemic therapy.

Hidradenitis suppurativa (HS).

Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients who have not responded to conventional systemic therapy.

Uveitis.

Humira is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients, did not respond to corticosteroid therapy, who require a reduction in the dose of corticosteroids, or who have intolerance to or medical contraindications to corticosteroid therapy.

In pediatrics

Juvenile rheumatoid (idiopathic) arthritis (JRA).

Polyarticular juvenile rheumatoid (idiopathic) arthritis

Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

Humira can be used as monotherapy in cases of methotrexate intolerance or when continued therapy methotrexate is unacceptable.

Enthesitis-associated arthritis

Humira is indicated for the treatment of active Enthesitis-associated arthritis in children aged 6 years and older who have not responded to conventional therapy, or in the presence of intolerance or medical contraindications to such types of therapy.

Crohn's disease (CD) in children.

Humira is indicated for the treatment of moderate to severe Crohn's disease in children 6 years of age and older who have not responded to conventional therapy, including primary nutritional therapy, corticosteroids, and/or immunomodulators, or who are intolerant or medically contraindicated to such therapies.

Plaque psoriasis (PP) in children.

Humira is indicated for the treatment of severe chronic plaque psoriasis in children 4 years of age and older who have not achieved a clinical response to, or are contraindicated in or intolerant of, topical therapy or phototherapy.